BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

ByJohn Garica

POMPANO BEACH, Fla., April 14, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacture, and commercialization of…

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers

ByJohn Garica

Feb 24, 2025 Study comparing BioStem’s proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion. POMPANO…

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

ByJohn Garica

POMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) —BioStem Technologies, Inc.(OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived…

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

ByJohn Garica

Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) —BioStem Technologies, Inc.(OTC: BSEM), a leading…

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

ByJohn Garica

Nov 25, 2024Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) — BioStem…